NIAGEN BIOSCIENCE INC(NASDAQ:NAGE) stock News

NAGE Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

a month ago - By: Niagen Bioscience, Inc

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

2 months ago - By: Benzinga

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

2 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

14 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

2 months ago - By: Zacks Investment Research - Mentions: CRVO

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

2 months ago - By: The Motley Fool

Niagen NAGE Q2 2025 Earnings Call Transcript

2 months ago - By: Niagen Bioscience, Inc.

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

3 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

3 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

3 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Participate in the BIO 2025 International Convention

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

5 months ago - By: Zacks Investment Research - Mentions: NVAX

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates

5 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

5 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

6 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

6 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

6 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

7 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

7 months ago - By: Niagen Bioscience, Inc

NIAGEN BIOSCIENCE INC (NAGE) Stock News

NAGE Latest News, Press Relases and Analysis

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

Earnings Scheduled For August 6, 2025

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Niagen NAGE Q2 2025 Earnings Call Transcript

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Niagen Bioscience to Participate in the BIO 2025 International Convention

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science